Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Treasury Shares: 2019-2024

Historic Treasury Shares for C4 Therapeutics (CCCC) over the last 5 years, with Dec 2024 value amounting to $1.5 million.

  • C4 Therapeutics' Treasury Shares rose 43183.48% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 43183.48%. This contributed to the annual value of $1.5 million for FY2024, which is 100.65% up from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Treasury Shares is $1.5 million, which was up 100.65% from $750,210 recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Treasury Shares ranged from a high of $1.5 million in FY2024 and a low of $43,972 during FY2020.
  • In the last 3 years, C4 Therapeutics' Treasury Shares had a median value of $750,210 in 2023 and averaged $906,930.
  • Data for C4 Therapeutics' Treasury Shares shows a peak YoY soared of 619.44% (in 2020) over the last 5 years.
  • Over the past 4 years, C4 Therapeutics' Treasury Shares (Yearly) stood at $43,972 in 2020, then reached $465,291 in 2022, then soared by 61.23% to $750,210 in 2023, then spiked by 100.65% to $1.5 million in 2024.